Loading
A phase 3 trial of pemetrexed and toripalimab in lung cancer, run by Shanghai Junshi Bioscience Co., Ltd., active but no longer recruiting.
JS001sc or JS001 Plus Chemotherapy is Indicated for Relapsed or Metastatic First-Line Non-Squamous Non Small Cell Lung Cancer（NSCLC） is a phase 3, randomised interventional study registered as NCT06505837 by Shanghai Junshi Bioscience Co., Ltd., with a registry enrolment figure of 395 participants, started 2024-07-11 and due to reach its primary completion in 2026-06-30. Interventions recorded: JS001sc (360mg Subcutaneous injection) and pemetrexed/platinum-containing chemotherapy; JS001 (240mg intravenous infusion) and pemetrexed/platinum-containing chemotherapy. Conditions listed: Recurrent Metastatic Non-Squamous Non Small Cell Lung Cancer. Primary outcome: Observed serum Ctrough at Cycle 1; Model-predicted area under the concentration-time curve(AUC) from 0 to 21 days at Cycle 1. Lung eligibility wording from the registry: "Histologically or cytologically confirmed relapsed or metastatic non-squamous NSCLC". Sites: China. No results are recorded here; the registry entry is the source.
Shares Pemetrexed, Lung cancer trials open today (registry snapshot), Cytotoxic chemotherapy, Non-small-cell lung cancer and the tag lung-deep-dive.
Shares Pemetrexed, Lung cancer trials open today (registry snapshot), Cytotoxic chemotherapy, Immune checkpoint inhibitors and the tag lung-deep-dive.
Shares Pemetrexed, Lung cancer trials open today (registry snapshot), Cytotoxic chemotherapy, Immune checkpoint inhibitors and the tag lung-deep-dive.
Shares Pemetrexed, Lung cancer trials open today (registry snapshot), Cytotoxic chemotherapy, Immune checkpoint inhibitors and the tag lung-deep-dive.
Shares Pemetrexed, Lung cancer trials open today (registry snapshot), Cytotoxic chemotherapy, Immune checkpoint inhibitors and the tag lung-deep-dive.
Shares Pemetrexed, Lung cancer trials open today (registry snapshot), Cytotoxic chemotherapy, Immune checkpoint inhibitors and the tag lung-deep-dive.
Shares Toripalimab, Lung cancer trials open today (registry snapshot), Cytotoxic chemotherapy, Immune checkpoint inhibitors and the tag lung-deep-dive.
Shares Pemetrexed, Lung cancer trials open today (registry snapshot), Cytotoxic chemotherapy, Immune checkpoint inhibitors and the tag lung-deep-dive.